カテゴリ： GlobalData, アメリカ, 企業調査

Matinas BioPharma Holdings Inc (MTNB)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Matinas BioPharma Holdings Inc (MTNB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9430
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Matinas BioPharma Holdings Inc (Matinas BioPharma) is a clinical-stage biopharmaceutical company that discovers and develops anti-infectives for orphan indications. The company develops lipid nano-crystal (LNC) technology, a drug delivery platform to deliver various molecules such as small molecules, oligonucleotides, proteins, peptides, vaccines, and gene editing technologies. Its pipeline products include MAT2203, an LNC formulation of amphotericin B used for the prevention of IFI in acute lymphoblastic leukaemia; and MAT2501, an LNC formulation of amikacin used for non-tuberculosis mycobacterium infections. It partners with pharmaceutical and biotech companies to develop its LNC platform. The company operates a laboratory in Bridgewater, New Jersey. Matinas BioPharma is headquartered in Bedminster, New Jersey, the US.

Matinas BioPharma Holdings Inc (MTNB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Matinas BioPharma Raises USD15.5 Million in Venture Financing 11
Matinas BioPharma Raises US$0.39 Million In Venture Financing 12
Matinas BioPharma Raises US$1 Million In Venture Financing 13
Partnerships 14
Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 14
Matinas BioPharma Enters into Agreement with Colorado State University 15
Licensing Agreements 16
Matinas BioPharma Enters Into Licensing Agreement with Rutgers University 16
Equity Offering 17
Matinas Biopharma Raises USD8 Million in Public Offering of Shares 17
Matinas BioPharma Raises USD13.5 Million in Private Placement of Shares upon Exercise of Warrants 19
Matinas BioPharma Raises USD13.5 million in Public Offering of Shares and Warrants 20
Matinas BioPharma Raises USD8 Million in Private Placement of Shares 21
Matinas BioPharma Raises Additional USD10 Million in Final Tranche of Private Placement of Units 22
Matinas BioPharma Completes Private Placement Of Shares For US$15 Million 24
Acquisition 25
Matinas BioPharma Acquires Aquarius BioTech 25
Matinas BioPharma Holdings Inc – Key Competitors 26
Matinas BioPharma Holdings Inc – Key Employees 27
Matinas BioPharma Holdings Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 10, 2018: Matinas BioPharma reports second quarter 2018 financial results and provides corporate update 29
May 10, 2018: Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update 31
Mar 26, 2018: Matinas BioPharma Reports 2017 Financial Results 32
Nov 15, 2017: Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update 33
Aug 08, 2017: Matinas BioPharma Reports 2017 Second Quarter Financial Results 35
May 16, 2017: Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update 36
Apr 03, 2017: Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update 37
Corporate Communications 39
Oct 15, 2018: Matinas BioPharma names Theresa Matkovits as Chief Development Officer 39
Dec 14, 2017: Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors 41
Apr 18, 2017: Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance 42
Mar 30, 2017: Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors 43
Feb 27, 2017: Matinas BioPharma Announces Trading on NYSE MKT to Commence March 2, 2017 44
Product News 45
08/03/2017: Matinas BioPharma to Provide Update on Anti-infective Product Candidate MAT2501 at Canaccord Genuity 37th Annual Growth Conference 45
01/26/2017: Matinas BioPharma Provides Business Outlook, Announces Update on MAT2501 46
01/26/2017: Matinas BioPharma Provides Provides Business Outlook, Announces Update on MAT2203 47
Clinical Trials 48
Mar 16, 2018: Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update 48
Jan 08, 2018: Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis 50
Sep 19, 2017: Matinas BioPharma to Present Data on MAT2203 at the Cantor Fitzgerald Global Healthcare Conference 52
Sep 19, 2017: Matinas BioPharma to Present Data on MAT2501 at the Cantor Fitzgerald Global Healthcare Conference 53
Aug 08, 2017: Matinas BioPharma Provides Update on MAT2501 54
Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 55
Aug 03, 2017: Matinas BioPharma to Provide Update on antifungal product candidate MAT2203 at the Canaccord Genuity 37th Annual Growth Conference 56
Jun 26, 2017: Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis 57
Jun 03, 2017: Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis 59
Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis 61
Jun 01, 2017: Matinas BioPharma to Provide Update on Antifungal Product Candidate, MAT2203, at the 2017 Jefferies Global Healthcare Conference 63
Jun 01, 2017: Matinas BioPharma to Provide Update on its Antibiotic Product Candidate, MAT2501, at the 2017 Jefferies Global Healthcare Conference 64
May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference 65
Mar 27, 2017: Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501 66
Mar 10, 2017: Matinas BioPharma to Present Update on antifungal product candidate MAT2203 at 29th Annual ROTH Conference 67
Mar 10, 2017: Matinas BioPharma to Present Update on MAT2501 at 29th Annual ROTH Conference 68
Mar 08, 2017: Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection 69
Mar 06, 2017: Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis 71
Jan 23, 2017: Matinas BioPharma to Present Update on MAT2203 at Noble Capital Markets’ Thirteenth Annual Investor Conference 72
Jan 23, 2017: Matinas BioPharma to Present Update on MAT2501 at Noble Capital Markets’ Thirteenth Annual Investor Conference 73
Jan 06, 2017: Matinas BioPharma to Present Update on MAT2203 at Biotech Showcase 2017 74
Jan 06, 2017: Matinas BioPharma to Present Update on MAT2501 at Biotech Showcase 2017 75
Other Significant Developments 76
Sep 25, 2018: Matinas BioPharma to present at the MicroCap Conference 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Matinas BioPharma Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Matinas BioPharma Raises USD15.5 Million in Venture Financing 11
Matinas BioPharma Raises US$0.39 Million In Venture Financing 12
Matinas BioPharma Raises US$1 Million In Venture Financing 13
Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 14
Matinas BioPharma Enters into Agreement with Colorado State University 15
Matinas BioPharma Enters Into Licensing Agreement with Rutgers University 16
Matinas Biopharma Raises USD8 Million in Public Offering of Shares 17
Matinas BioPharma Raises USD13.5 Million in Private Placement of Shares upon Exercise of Warrants 19
Matinas BioPharma Raises USD13.5 million in Public Offering of Shares and Warrants 20
Matinas BioPharma Raises USD8 Million in Private Placement of Shares 21
Matinas BioPharma Raises Additional USD10 Million in Final Tranche of Private Placement of Units 22
Matinas BioPharma Completes Private Placement Of Shares For US$15 Million 24
Matinas BioPharma Acquires Aquarius BioTech 25
Matinas BioPharma Holdings Inc, Key Competitors 26
Matinas BioPharma Holdings Inc, Key Employees 27
Matinas BioPharma Holdings Inc, Subsidiaries 28

List of Figures
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Matinas BioPharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Matinas BioPharma Holdings Inc (MTNB)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Neurim Pharmaceuticals Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Neurim Pharmaceuticals Ltd (Neurim) is a drug discovery company that develops drugs for central nervous system diseases.The company's product line includes circadin that is used in insomnia treatment. Neurim offers paediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. Th …
  • BrainLAB AG：企業の戦略的SWOT分析
    BrainLAB AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • UCB SA (UCB)-製薬・医療分野：企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Telecom Italia S.p.A.：企業の戦略・SWOT・財務情報
    Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The US Oncology Network：企業の戦略的SWOT分析
    The US Oncology Network - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Ford Motor Company：企業の戦略・SWOT・財務分析
    Ford Motor Company - Strategy, SWOT and Corporate Finance Report Summary Ford Motor Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Obsidian Energy Ltd (OBE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Obsidian Energy Ltd (Obsidian) is formerly known as Penn West Petroleum Ltd. It is a conventional oil and natural gas production and development company in Canada with a well-balanced portfolio of high-quality assets. It develops and explores oil and gas properties and related production inf …
  • PDL BioPharma Inc (PDLI)：製薬・医療：M&Aディール及び事業提携情報
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Dana Petroleum Ltd：企業の戦略的SWOT分析
    Dana Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Mersen SA (MRN)：企業の財務・戦略的SWOT分析
    Mersen SA (MRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Global Telecom Holding S.A.E. (GLTD)：企業の財務・戦略的SWOT分析
    Global Telecom Holding S.A.E. (GLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Philips Healthcare-製薬・医療分野：企業M&A・提携分析
    Summary Philips Healthcare, formerly Philips Medical Systems, undertakes the manufacture and distribution of diagnostic imaging systems, healthcare information technology solutions, patient monitoring and cardiac devices. Philips Healthcare is a division of Royal Philips Electronics of the Netherlan …
  • Stratasys Ltd：企業の戦略・SWOT・財務情報
    Stratasys Ltd - Strategy, SWOT and Corporate Finance Report Summary Stratasys Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Red Rock Resorts, Inc. (RRR)：企業の財務・戦略的SWOT分析
    Red Rock Resorts, Inc. (RRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • MemorialCare Health System：製薬・医療：M&Aディール及び事業提携情報
    Summary MemorialCare Health System (MemorialCare) is a non-profit health system that offers medical services. The center offers care services such as stroke care, cancer care, rehabilitation and physical therapy, weight-loss surgery, heart and vascular care, breast care, imaging and radiology, labor …
  • Xcel Energy Inc (XEL)-石油・ガス分野：企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Fukoku Mutual Life Insurance Company：企業の戦略・SWOT・財務情報
    Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Envision Healthcare Corp：戦略・SWOT・企業財務分析
    Envision Healthcare Corp - Strategy, SWOT and Corporate Finance Report Summary Envision Healthcare Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SM Energy Co (SM)：企業の財務・戦略的SWOT分析
    SM Energy Co (SM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Astaldi S.p.A.：戦略・SWOT・企業財務分析
    Astaldi S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Astaldi S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆